Your browser doesn't support javascript.
loading
Novel CHK1 inhibitor MU380 exhibits significant single-agent activity in TP53-mutated chronic lymphocytic leukemia cells.
Boudny, Miroslav; Zemanova, Jana; Khirsariya, Prashant; Borsky, Marek; Verner, Jan; Cerna, Jana; Oltova, Alexandra; Seda, Vaclav; Mraz, Marek; Jaros, Josef; Jaskova, Zuzana; Spunarova, Michaela; Brychtova, Yvona; Soucek, Karel; Drapela, Stanislav; Kasparkova, Marie; Mayer, Jiri; Paruch, Kamil; Trbusek, Martin.
Afiliación
  • Boudny M; Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University.
  • Zemanova J; Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University.
  • Khirsariya P; Department of Chemistry, CZ Openscreen, Faculty of Science, Masaryk University.
  • Borsky M; Center of Biomolecular and Cellular Engineering, International Clinical Research Center, St. Anne's University Hospital.
  • Verner J; Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University.
  • Cerna J; Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University.
  • Oltova A; Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University.
  • Seda V; Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University.
  • Mraz M; Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University.
  • Jaros J; Center of Molecular Medicine, Central European Institute of Technology, Masaryk University.
  • Jaskova Z; Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University.
  • Spunarova M; Center of Molecular Medicine, Central European Institute of Technology, Masaryk University.
  • Brychtova Y; Department of Histology and Embryology, Faculty of Medicine, Masaryk University.
  • Soucek K; Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University.
  • Drapela S; Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University.
  • Kasparkova M; Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University.
  • Mayer J; Center of Biomolecular and Cellular Engineering, International Clinical Research Center, St. Anne's University Hospital.
  • Paruch K; Department of Cytokinetics, Institute of Biophysics CAS, v.v.i.
  • Trbusek M; Department of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic.
Haematologica ; 104(12): 2443-2455, 2019 12.
Article en En | MEDLINE | ID: mdl-30975914

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Piperidinas / Pirazoles / Pirimidinas / Leucemia Linfocítica Crónica de Células B / Regulación Neoplásica de la Expresión Génica / Proteína p53 Supresora de Tumor / Sinergismo Farmacológico / Quinasa 1 Reguladora del Ciclo Celular (Checkpoint 1) / Mutación Límite: Animals / Female / Humans Idioma: En Revista: Haematologica Año: 2019 Tipo del documento: Article Pais de publicación: Italia

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Piperidinas / Pirazoles / Pirimidinas / Leucemia Linfocítica Crónica de Células B / Regulación Neoplásica de la Expresión Génica / Proteína p53 Supresora de Tumor / Sinergismo Farmacológico / Quinasa 1 Reguladora del Ciclo Celular (Checkpoint 1) / Mutación Límite: Animals / Female / Humans Idioma: En Revista: Haematologica Año: 2019 Tipo del documento: Article Pais de publicación: Italia